India to Azerbaijan: Linagliptin Export Trade Route

The India to Azerbaijan Linagliptin corridor is one of India's established pharmaceutical export routes, with 2 shipments documented worth a combined $62.4K USD. The route is dominated by ANNORA PHARMA PRIVATE LIMITED, which alone accounts for roughly 100% of all export value, reflecting the consolidated nature of India's linagliptin manufacturing sector.

Across 1 active suppliers, the average shipment value stands at $31.2K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Freight is split between sea (68%) and air (17%), suggesting a mix of scheduled bulk orders and time-sensitive consignments.

Shipment activity peaks during January–March, with an average transit time of 28 days port-to-port. The route has recorded an annual growth rate of 17.0%, placing it at rank #2 among India's top linagliptin export destinations globally.

On the import side, key buyers of Indian linagliptin in Azerbaijan include B-MED LLC. B-MED LLC is the single largest importer with 2 shipments valued at $62.4K USD.

India's linagliptin exports to Azerbaijan are driven primarily by a handful of large-scale manufacturers. ANNORA PHARMA PRIVATE LIMITED with 2 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 1 active exporters signals a competitive but concentrated market — buyers in Azerbaijan benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — ANNORA PHARMA PRIVATE LIMITED — together account for 100% of total trade value on this route. The average shipment value of $31.2K USD reflects a mix of bulk commercial orders and smaller specialty shipments.

On the buying side, B-MED LLC is the largest importer with 2 shipments worth $62.4K USD — representing 100% of all linagliptin imports from India on this route.